Pre-operative Plasma Levels of Thrombin-Antithrombin III Complexes Correlate with the Development of Venous Thrombosis after Major Hip or Knee Surgery

Summary

Study objective. To determine whether levels of thrombin-antithrombin III (TAT) in plasma, taken two weeks pre-operatively, predict the development of deep vein thrombosis (DVT) in patients undergoing major hip or knee surgery.

Design. Prospective cohort.

Setting. Tertiary-care referral centre, university-affiliated hospital.

Patients. Ninety eight consecutive patients undergoing elective hip or knee surgery.

Intervention. All eligible consenting patients were seen in a preoperative clinic two weeks prior to surgery and had blood taken for measurement of plasma TAT level. After surgery, they received a combination of unfractionated heparin 5000 Units 12-hourly subcutaneously, and antiembolism stockings (TEDS), as prophylaxis against DVT. Contrast venography was performed prior to discharge, and according to the results, patients were classified as having proximal (popliteal and/or more proximal) DVT (n = 12), calf DVT (n = 7) or no DVT (n = 79).

Measurements and Results. The mean TAT level was significantly higher in patients who developed DVT (5.7 μg/l) than in those who did not (4.1 μg/l), p = 0.035. Using cut-points of 3.5 and 5.5 μg/l for the TAT level, patients could be categorized as high, intermediate, and low risk for the development of DVT. The proportion of patients with TAT levels of ≥3.5μg/l who developed calf or proximal DVT was significantly higher than the proportion of patients with TAT levels of <3.5 μg/l who developed calf or proximal DVT (p = 0.02). The proportion of patients with TAT levels >5.5 μg/l who developed proximal DVT was significantly higher than the proportion of patients with TAT levels of ≤5.5 μg/l who developed proximal DVT (p = 0.03).

Conclusions. This study demonstrates that pre-operative TAT levels correlate with the risk of developing DVT after major orthopedic surgery. Further studies are needed to determine the reason(s) for this observation and whether rational recommendations about prophylaxis and screening for DVT can be made based on the results of a pre-operative TAT level.

• References

• 1 Ofosu F, Agnelli G, Hirsh J. New thrombin inhibitors: Mode of action, experimental findings and clinical potential. In: Recent Advances In Haematology. Hoffbrand V, Brenner MK. (eds) London, England: Churchill, Livingstone; 1992. pp 45-72
• 2 Aronson DL, Stevan L, Ball AP, Franza Jr BR, Finlayson JS. Generation of the combined activation peptide (FI.2) during the clotting of blood and plasma. J Clin Invest 1977; 60: 1410-1418
• 3 Teitel JM, Bauer KA, Lau UK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/FI+2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097
• 4 Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in blood. J Clin Invest 1974; 54: 43-53
• 5 Bauer KA, Goodman TL, Kass BL. Rosenberg Llevatcd factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest 1985; 76: 826-836
• 6 Demers C, Ginsberg JS, Henderson P, Ofosu F, Weitz JI, Blajchman MA. Measurement of markers of activated coagulation in antithrombin III deficient subjects. Thromb Hacmost 1992; 67: 542-544
• 7 Mannucci PM, Tripodi A, Bottasso B, Baudo F, Finazzi G, De Stefano V, Palareti G, Manotti C, Mazzucconi MG, Castaman G. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992; 67: 200-202
• 8 Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in Antithrombin-III-deficient Persons. Report of a Large Kindred and Literature Review Ann Intern Med 1992; 116: 754-761
• 9 Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, Weitz J, Denburg JA. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies; Lvidence fora prothrombotic state. Blood 1993; 81: 2958-2963
• 10 Ofosu FA, Lederc J, Delorme F, Craven S, Shafai S, Frewin L, Blajchman MA. The low molecular weight heparin Lnoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery. Br J Haemal 1992; 82: 391-399
• 11 Demers C, Ginsberg JS, Johnston M, Brill-Edwards P, Panju A. D-Dimer and Thrombin-Antithrombin III Complexes in Patients with Clinically Suspected Pulmonary Lmbolism. Thromb Haemost 1992; 67: 408-412
• 12 Demers C, Ginsberg JS, Brill-Ldwards P, Panju A, McGinnis J. Heparin and Graduated Compression Stockings in Patients Undergoing Fractured Hip Surgery. J Ortho Trauma 1991; 5: 387-391
• 13 Warkentin TL, Kelton JG. Heparin and Platelets. Hemal Oncol Clin North Am 1990; 4: 243-257
• 14 Hirsh J, Levine M. Prevention of venous thrombosis in patients undergoing major orthopaedic surgical procedures. Br J Clin Pract 1989; 65: 2-8
• 15 Hoek JA, Nurmohamed MT, ten Cate JW, Büller HR, Knipscheer HC, Hamelynck KJ, Marti RK, Sturk A. Thrombin-Antithrombin III Complexes in the Prediction of Deep Vein Thrombosis Following Total Hip Replacement. Thromb Haemost 1989; 62: 1050-1052